title: Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  Positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose ((18) F-FDG) is considered to be the most beneficial imaging method for staging patients with non-Hodgkin's lymphoma (NHL). The intensity of (18) F-FDG accumulation may be determined by calculating the so-called standardised uptake value (SUV). The study aimed at assessing the benefit of SUV(max) determination in staging (18) F-FDG PET/CT in untreated patients with NHL.
  
  
  METHODS
  One hundred and forty-nine initial staging (18) F-FDG PET/CT scans performed in patients with NHL between January 2007 and August 2009 were assessed, and the SUV(max) was determined.
  
  
  RESULTS
  The highest mean and median values of SUV(max) were observed in patients with diffuse large B-cell lymphoma (DLBCL), the lowest mean and median values were found in small lymphocytic lymphoma. The overlap in SUV(max) < 10 between DLBCL and the other subgroups of NHL was very significant. Statistically, no correlation was found between the lactate dehydrogenase and SUV(max) values. On the other hand, a correlation of the Ki-67 proliferative index of tumour cells and SUV(max) was revealed (r = 0.409, P < 0.001). The geometric mean of SUV(max) in patients with Ki-67 ≤ 60 and those with Ki-67 > 60 was 8.8 and 14.3, respectively (P < 0.001).
  
  
  CONCLUSIONS
  The results confirm that SUV(max) is not beneficial for making a more precise diagnosis in most patients with NHL. Correlation of SUV(max) with the Ki-67 values suggests that SUV(max) might have a prognostic values in NHL.
authors.affiliation: Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. tomas.papajik@fnol.cz
authors.forename: Tomáš
authors.initials: T
authors.lastname: Papajík
authors.forename: Miroslav
authors.initials: M
authors.lastname: Mysliveček
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Sedová
authors.forename: Eva
authors.initials: E
authors.lastname: Buriánková
authors.forename: Vít
authors.initials: V
authors.lastname: Procházka
authors.forename: Pavel
authors.initials: P
authors.lastname: Koranda
authors.forename: Luděk
authors.initials: L
authors.lastname: Raida
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Kubová
authors.forename: Miroslava
authors.initials: M
authors.lastname: Palová
authors.forename: Ladislava
authors.initials: L
authors.lastname: Kučerová
authors.forename: Patrik
authors.initials: P
authors.lastname: Flodr
authors.forename: Jiří
authors.initials: J
authors.lastname: Jarkovský
authors.forename: Ladislav
authors.initials: L
authors.lastname: Dušek
authors.forename: Karel
authors.initials: K
authors.lastname: Indrák
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods* / Q000592:standards; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D011379:Prognosis; D012680:Sensitivity and Specificity
chemical_list: D019394:Ki-67 Antigen; D019788:Fluorodeoxyglucose F18; D007770:L-Lactate Dehydrogenase